A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509

Cancer Discovery

Volumn 3, Issue 9, 2013, Pages 1020-1029

  Joseph, James D ^a   Lu, Nhin ^a   Qian, Jing ^a   Sensintaffar, John ^a   Shao, Gang ^a   Brigham, Dan ^a   Moon, Michael ^a   Maneval, Edna Chow ^a   Chen, Isan ^a   Darimont, Beatrice ^a   Hager, Jeffrey H ^a  

^a Aragon Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5ALPHA ANDROSTAN 3 ONE; ANDROGEN RECEPTOR; ANTIANDROGEN; ARN509; ENZALUTAMIDE; LUCIFERASE; MESSENGER RNA; PARTIAL AGONIST; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; CELL LINE, TUMOR; DNA; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; THIOHYDANTOINS;

EID: 84885210324     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0226     Document Type: Article

References (26)

1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplifi cation. Science 2001; 293: 876-80.
2. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 2011; 17: 212-21.
3. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27: 36-41.
4. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
5. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, Macdonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifi es potential therapeutic targets and disease heterogeneity. Eur Urol 2013; 63: 920-6.
6. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-53.
7. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-40.
8. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
9. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72: 1494-503.
10. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9.
11. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 2012; 367: 1187-97.
12. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager J, et al. A phase I study of ARN-509, a novel antiandrogen for the treatment of castration-resistant prostate cancer. J Clin Oncol 2013 (article in press).
13. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 703-6.
14. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 1383-8.
15. Robins DM. Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men. Mol Cell Endocrinol 2012; 352: 26-33.
16. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808.
17. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 1999; 13: 440-54.
18. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fl uorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 2003; 100: 8817-22.
19. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-90.
20. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013; 2: e00499.
21. Rathkopf DE, Shore N, Antonarakis ES, Berry WR, Alumkal JJ, Tutrone R, et al. A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 30, 2012 (suppl; abstr TPS4697).
22. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71: 480-8.
23. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006; 10: 309-19.
24. Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res 2006; 66: 10513-6.
25. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108.
26. Joseph JD, Wittmann BM, Dwyer MA, Cui H, Dye DA, McDonnell DP, et al. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci U S A 2009; 106: 12178-83.